{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:36:16Z","timestamp":1790951776828,"version":"4.1.0"},"reference-count":116,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Melanoma is the leading cause of global skin cancer-related death and currently ranks as the third most commonly diagnosed cancer in Australia. Melanoma patients with in-transit metastases (ITM), a type of locoregional metastasis located close to the primary tumor site, exhibit a high likelihood of further disease progression and poor survival outcomes. Immunotherapies, particularly immune checkpoint inhibitors (ICI), have demonstrated remarkable efficacy in ITM patients with reduced occurrence of further metastases and prolonged survival. The major challenge of immunotherapeutic efficacy lies in the limited understanding of melanoma and ITM biology, hindering our ability to identify patients who likely respond to ICIs effectively. In this review, we provided an overview of melanoma and ITM disease. We outlined the key ICI therapies and the critical immune features associated with therapy response or resistance. Lastly, we dissected the underlying biological components, including the cellular compositions and their communication networks within the tumor compartment, to enhance our understanding of the interactions between immunotherapy and melanoma, providing insights for future investigation and the development of drug targets and predictive biomarkers.<\/jats:p>","DOI":"10.3390\/ijms25084243","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T09:37:31Z","timestamp":1712828251000},"page":"4243","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Understanding the Tumor Microenvironment in Melanoma Patients with In-Transit Metastases and Its Impacts on Immune Checkpoint Immunotherapy Responses"],"prefix":"10.3390","volume":"25","author":[{"given":"Jiabao","family":"Tian","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camelia","family":"Quek","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Saginala, K., Barsouk, A., Aluru, J.S., Rawla, P., and Barsouk, A. (2021). Epidemiology of Melanoma. Med. Sci., 9.","DOI":"10.3390\/medsci9040063"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ejca.2015.07.039","article-title":"Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study","volume":"51","author":"Crocetti","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_4","first-page":"1071","article-title":"Cutaneous melanoma: From pathogenesis to therapy","volume":"52","author":"Leonardi","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_5","first-page":"228","article-title":"Black lesions of the skin","volume":"88","author":"Becker","year":"1958","journal-title":"Calif. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"ref_7","first-page":"66","article-title":"Melanocytic tumour classification and the pathway concept of melanoma pathogenesis","volume":"11","author":"Elder","year":"2018","journal-title":"World Health Organ. Classif. Tumours"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","article-title":"Cutaneous melanoma","volume":"402","author":"Long","year":"2023","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","article-title":"The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: Implications for melanoma treatment and care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1245\/s10434-014-4100-0","article-title":"In-transit melanoma metastases: Incidence, prognosis, and the role of lymphadenectomy","volume":"22","author":"Read","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_12","first-page":"572","article-title":"Survival rates of patients with metastatic malignant melanoma","volume":"7","author":"Sandru","year":"2014","journal-title":"J. Med. Life"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Weide, B., Faller, C., Buttner, P., Pflugfelder, A., Leiter, U., Eigentler, T.K., Bauer, J., Forschner, A., Meier, F., and Garbe, C. (2013). Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0063137"},{"key":"ref_14","first-page":"29","article-title":"Biologic behavior and treatment of intransit metastasis of melanoma","volume":"150","author":"Karakousis","year":"1980","journal-title":"Surg. Gynecol. Obstet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2022.03.041","article-title":"The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases\u2014A multicenter cohort study","volume":"169","author":"Holmberg","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1054\/bjps.1998.3050","article-title":"The pathogenesis of local recurrence of melanoma at the primary excision site","volume":"52","author":"Heenan","year":"1999","journal-title":"Br. J. Plast. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1445-2197.2002.02376.x","article-title":"Melanoma: Margins for error\u2014Another view","volume":"72","author":"McCarthy","year":"2002","journal-title":"ANZ J. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1365-2559.2012.04279.x","article-title":"Angiotropism is an independent predictor of microscopic satellites in primary cutaneous melanoma","volume":"61","author":"Wilmott","year":"2012","journal-title":"Histopathology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e000440","DOI":"10.1136\/jitc-2019-000440","article-title":"Efficacy of immune checkpoint inhibitors for in-transit melanoma","volume":"8","author":"Rtshiladze","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/jso.24921","article-title":"Intralesional PV-10 for the treatment of in-transit melanoma metastases-Results of a prospective, non-randomized, single center study","volume":"117","author":"Read","year":"2018","journal-title":"J. Surg. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2021.04.032","article-title":"Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases","volume":"152","author":"Zaremba","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1245\/ASO.2005.05.025","article-title":"Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy","volume":"12","author":"Pawlik","year":"2005","journal-title":"Ann. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.suc.2019.09.001","article-title":"Surgical Management of Primary Cutaneous Melanoma","volume":"100","author":"Joyce","year":"2020","journal-title":"Surg. Clin. N. Am."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.amjsurg.2023.10.035","article-title":"Is therapeutic lymph node dissection of value for lymph node recurrence in melanoma?","volume":"228","author":"Wilson","year":"2024","journal-title":"Am. J. Surg."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): A multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.annonc.2023.01.004","article-title":"Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials","volume":"34","author":"Versluis","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/ans.14921","article-title":"Management of in-transit melanoma metastases: A review","volume":"89","author":"Henderson","year":"2019","journal-title":"ANZ J. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/jso.25400","article-title":"A systematic review and meta-analysis of locoregional treatments for in-transit melanoma","volume":"119","author":"Read","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1245\/s10434-014-4169-5","article-title":"Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma","volume":"22","author":"Thompson","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1158\/1078-0432.CCR-17-3436","article-title":"Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study","volume":"24","author":"Atkins","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1200\/JCO.2017.72.2850","article-title":"Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study","volume":"36","author":"Callahan","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study","volume":"37","author":"Garon","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.18.01998","article-title":"Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb\/IV CheckMate 511 Trial","volume":"37","author":"Lebbe","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.annonc.2020.11.020","article-title":"Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer","volume":"32","author":"Perets","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"101405","DOI":"10.1016\/j.tranon.2022.101405","article-title":"Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response","volume":"20","author":"Rupp","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/eji.202048747","article-title":"Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action","volume":"51","author":"Willsmore","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1\/Anti-CTLA-4 Combined Therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"155124","DOI":"10.1016\/j.prp.2024.155124","article-title":"Lymphocyte-activation gene 3 (LAG-3) as a promising immune checkpoint in cancer immunotherapy: From biology to the clinic","volume":"254","author":"Alqurashi","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbrc.2023.07.058","article-title":"Molecular and structural basis of TIGIT: Nectin-4 interaction, a recently discovered pathway crucial for cancer immunotherapy","volume":"677","author":"Ganguli","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"eadg6752","DOI":"10.1126\/scitranslmed.adg6752","article-title":"Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models","volume":"15","author":"Ma","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Rotte, A., Sahasranaman, S., and Budha, N. (2021). Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development. Biomedicines, 9.","DOI":"10.3390\/biomedicines9091277"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"107933","DOI":"10.1016\/j.intimp.2021.107933","article-title":"TIM-3: An update on immunotherapy","volume":"99","author":"Zhao","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41587-019-0280-2","article-title":"Predicting HLA class II antigen presentation through integrated deep learning","volume":"37","author":"Chen","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"eabb6852","DOI":"10.1126\/sciimmunol.abb6852","article-title":"Tissue-resident CD4(+) T helper cells assist the development of protective respiratory B and CD8(+) T cell memory responses","volume":"6","author":"Son","year":"2021","journal-title":"Sci. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"104119","DOI":"10.1016\/j.cellimm.2020.104119","article-title":"The roles of tumor-associated macrophages in tumor angiogenesis and metastasis","volume":"353","author":"Fu","year":"2020","journal-title":"Cell Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1172\/JCI87324","article-title":"Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma","volume":"126","author":"Daud","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4(+) T cells in cancer immunotherapy-new insights into old paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"990463","DOI":"10.3389\/fimmu.2022.990463","article-title":"Immunotherapy of targeting MDSCs in tumor microenvironment","volume":"13","author":"Sui","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00262-017-2072-1","article-title":"Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy","volume":"67","author":"Balatoni","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1158\/1078-0432.CCR-18-3488","article-title":"Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab","volume":"25","author":"Hamid","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12032-018-1080-0","article-title":"The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma","volume":"35","author":"Uryvaev","year":"2018","journal-title":"Med. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1158\/1078-0432.CCR-18-2652","article-title":"Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma","volume":"25","author":"Wong","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.immuni.2019.10.009","article-title":"CD4(+) T Cell Help Is Required for the Formation of a Cytolytic CD8(+) T Cell Subset that Protects against Chronic Infection and Cancer","volume":"51","author":"Zander","year":"2019","journal-title":"Immunity"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.immuni.2019.12.007","article-title":"Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4(+) T Cells","volume":"52","author":"Sledzinska","year":"2020","journal-title":"Immunity"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma","volume":"175","author":"Yizhak","year":"2018","journal-title":"Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e000442","DOI":"10.1136\/esmoopen-2018-000442","article-title":"Implementing TMB measurement in clinical practice: Considerations on assay requirements","volume":"4","author":"Buttner","year":"2019","journal-title":"ESMO Open"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00262-020-02777-4","article-title":"CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)","volume":"70","author":"Fietz","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e96793","DOI":"10.1172\/jci.insight.96793","article-title":"CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients","volume":"3","author":"Goltz","year":"2018","journal-title":"JCI Insight"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1158\/1078-0432.CCR-16-0698","article-title":"Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma","volume":"23","author":"Vilain","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.4049\/jimmunol.170.5.2516","article-title":"CD4+CD25\u2212 T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-beta-dependent mechanism","volume":"170","author":"Oida","year":"2003","journal-title":"J. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: A moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","article-title":"A decade of checkpoint blockade immunotherapy in melanoma: Understanding the molecular basis for immune sensitivity and resistance","volume":"23","author":"Huang","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-15-0676","article-title":"Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab","volume":"21","author":"Gebhardt","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3Kgamma is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1158\/2326-6066.CIR-18-0272","article-title":"Intracellular Activation of Complement C3 Leads to PD-L1 Antibody Treatment Resistance by Modulating Tumor-Associated Macrophages","volume":"7","author":"Zha","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"9865","DOI":"10.1038\/s41598-023-36942-3","article-title":"Fc-competent multispecific PDL-1\/TIGIT\/LAG-3 antibodies potentiate superior anti-tumor T cell response","volume":"13","author":"Yang","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1926762","DOI":"10.1080\/2162402X.2021.1926762","article-title":"Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients","volume":"10","author":"Machiraju","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2261248","DOI":"10.1080\/2162402X.2023.2261248","article-title":"Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies","volume":"12","author":"Gide","year":"2023","journal-title":"Oncoimmunology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"10070","DOI":"10.1200\/JCO.2020.38.15_suppl.10070","article-title":"Checkpoint inhibitor treatment in patients with isolated in-transit melanoma metastases","volume":"38","author":"Storey","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s43018-023-00521-2","article-title":"CD4(+) T cells in cancer","volume":"4","author":"Speiser","year":"2023","journal-title":"Nat. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Jorgovanovic, D., Song, M., Wang, L., and Zhang, Y. (2020). Roles of IFN-gamma in tumor progression and regression: A review. Biomark. Res., 8.","DOI":"10.1186\/s40364-020-00228-x"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1158\/0008-5472.CAN-11-3218","article-title":"Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma","volume":"72","author":"Erdag","year":"2012","journal-title":"Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41467-017-00452-4","article-title":"Tumor-associated B-cells induce tumor heterogeneity and therapy resistance","volume":"8","author":"Somasundaram","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1038\/s41467-019-12160-2","article-title":"B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma","volume":"10","author":"Griss","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1126\/science.aao0505","article-title":"Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity","volume":"359","author":"Tay","year":"2018","journal-title":"Science"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control","volume":"172","author":"Bottcher","year":"2018","journal-title":"Cell"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40425-019-0565-5","article-title":"Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen","volume":"7","author":"Wculek","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1039\/D3MA00820G","article-title":"Melanoma immunotherapy enabled by M2 macrophage targeted immunomodulatory cowpea mosaic virus","volume":"5","author":"Zhao","year":"2024","journal-title":"Mater. Adv."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e170762","DOI":"10.1172\/JCI170762","article-title":"Enhancing immunotherapy response in melanoma: Myeloid-derived suppressor cells as a therapeutic target","volume":"133","author":"Lasser","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_102","first-page":"11","article-title":"Arginine deprivation therapy for malignant melanoma","volume":"5","author":"Yoon","year":"2013","journal-title":"Clin. Pharmacol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"Teng","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Papaccio, F., Kovacs, D., Bellei, B., Caputo, S., Migliano, E., Cota, C., and Picardo, M. (2021). Profiling Cancer-Associated Fibroblasts in Melanoma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147255"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"790113","DOI":"10.3389\/fimmu.2022.790113","article-title":"Immunological Classification of Tumor Types and Advances in Precision Combination Immunotherapy","volume":"13","author":"Ren","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"622509","DOI":"10.3389\/fimmu.2020.622509","article-title":"Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy","volume":"11","author":"Jiang","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41590-022-01179-1","article-title":"Dynamic transcriptional activity and chromatin remodeling of regulatory T cells after varied duration of interleukin-2 receptor signaling","volume":"23","author":"Moro","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"327ra326","DOI":"10.1126\/scitranslmed.aad6352","article-title":"The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis","volume":"8","author":"Mlecnik","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"996721","DOI":"10.3389\/fimmu.2022.996721","article-title":"A review of spatial profiling technologies for characterizing the tumor microenvironment in immuno-oncology","volume":"13","author":"Hu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41416-022-02119-4","article-title":"Tumour-infiltrating lymphocytes: From prognosis to treatment selection","volume":"128","author":"Brummel","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41374-021-00653-y","article-title":"Establishing standardized immune phenotyping of metastatic melanoma by digital pathology","volume":"101","author":"Sobottka","year":"2021","journal-title":"Lab. Investig."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/2159-8290.CD-21-1357","article-title":"The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution","volume":"12","author":"Nirmal","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Petitprez","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/8\/4243\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:26:27Z","timestamp":1760106387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/8\/4243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,11]]},"references-count":116,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["ijms25084243"],"URL":"https:\/\/doi.org\/10.3390\/ijms25084243","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,11]]}}}